PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Global research effort leads to new findings on genes and obesity

Einstein researcher part of team that finds genes linked to body shape and body mass index

2010-10-13
(Press-News.org) October 10, 2010─(BRONX, NY) ─Two major international studies looking at data from a quarter of a million people around the globe have found a new set of genes associated with body fat distribution and obesity. Researchers at 280 institutions worldwide, including Albert Einstein College of Medicine of Yeshiva University, conducted the studies. The research, published in the October 10 online edition of Nature Genetics, sheds light on the biological processes involved in body fat distribution, possibly leading to new ways of treating obesity.

"These studies open the door to better understanding the mechanisms that lead to the most harmful forms of obesity, which can result in heart attack, stroke and diabetes," said Robert Kaplan, Ph.D., professor of epidemiology & population health at Einstein and a co-author of the studies. "The findings provide important leads for researchers who are working to develop new medications to treat or prevent obesity."

In one study, researchers identified 13 new gene regions where variations in DNA sequence can be linked to a person's fat distribution—whether they store fat around the mid-section or below the waist. In the second study, researchers found 18 new genetic variations associated with increased susceptibility to obesity. The first study included data from almost 200,000 people, while the second study included data from nearly 250,000 people. Both studies were led by researchers at Oxford University and the Medical Research Council (MRC) Epidemiology Unit in Cambridge, England.

Using data from the large sample pool helped reveal genes that are exerting very subtle effects on body weight. "A lot of the genes we found were surprises," said Dr. Kaplan. "For every one of the new genes identified, we now can pose several new research questions to find out why it is associated with obesity."

The first study looked at a person's waist-to-hip ratio, which indicates a person's body shape. Someone who stores more fat around the waist (apple-shaped) is at greater risk of developing type 2 diabetes and heart disease, compared with someone who stores fat mainly in the thighs and buttocks (pear-shaped). The researchers note that while there are clear differences in body shape between men, who are more likely to be apple-shaped, and women, who are likelier to be pear-shaped, the mechanisms underlying these differences are not well understood. They found that genetic variations linked to where a person's body fat collects have a markedly stronger impact on women than on men. They also found that the genetic influences on body fat distribution are generally not the same as those involved in the risk of obesity.

The genes identified in the first study explain only about one percent of the variation in waist-to-hip ratios among different people. "But just because the percentage is very small, it doesn't mean that the finding isn't biologically important," Dr. Kaplan said. "We've learned in other areas of medicine that seemingly small influences can have a large impact, such as the correlation of high cholesterol to heart disease, for example. While high cholesterol doesn't account for a huge fraction of heart attack risk, we have been able to reduce the risk of heart attack in many patients by lowering cholesterol."

In the second study, the researchers examined the association between genes and body mass index (BMI), a measure of whether an individual's weight is healthy for a person of his or her height. An adult with a BMI of 25-29.9 is considered overweight, while a person with a BMI of 30 or greater is defined as obese. The study found 18 new genetic regions linked to BMI, bringing the known DNA variations linked to BMI to 32.

The study also revealed that a person of average height who inherited many of the "BMI-increasing" gene variants would weigh 15 to 20 pounds more than another person who inherited few of these variants. However, despite this large difference, the 32 confirmed genetic variations explain only 1.45% of the variation in people's BMIs. This suggests that a person's weight can be influenced by many other factors yet to be discovered, the researchers say.

"Clearly, genetics is not the whole story when it comes to obesity," Dr. Kaplan said. "The prevalence of obesity has skyrocketed in recent years, especially here in the Bronx, and our genes have not changed in that short period of time. Environmental factors, ranging from what we eat to how physically active we are, play a large role. But genetics are important because they may help us in terms of finding new obesity treatments, which so far have proven disappointing."

### The studies were carried out by the GIANT (Genetic Investigation of Anthropometric Traits) consortium, an international collaboration of more than 400 scientists who receive funding support from many funding agencies worldwide.

The papers, "Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index" and "Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution," were published in the October 10 online edition of Nature Genetics.

About Albert Einstein College of Medicine of Yeshiva University

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2009-2010 academic year, Einstein is home to 722 M.D. students, 243 Ph.D. students, 128 students in the combined M.D./Ph.D. program, and approximately 350 postdoctoral research fellows. The College of Medicine has 2,775 fulltime faculty members located on the main campus and at its clinical affiliates. In 2009, Einstein received more than $155 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five medical centers in the Bronx, Manhattan and Long Island - which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein - the College of Medicine runs one of the largest post-graduate medical training programs in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.einstein.yu.edu



ELSE PRESS RELEASES FROM THIS DATE:

NFL players with concussions now sidelined longer

2010-10-13
Los Angeles, CA (October 11, 2010) NFL players with concussions now stay away from the game significantly longer than they did in the late 1990s and early 2000s, according to research in Sports Health (owned by American Orthopaedic Society for Sports Medicine and published by SAGE). The mean days lost with concussion increased from 1.92 days during 1996-2001 to 4.73 days during 2002-2007. In an effort to discover whether concussion injury occurrence and treatment had changed, researchers compared those two consecutive six-year periods to determine the circumstances of ...

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

2010-10-13
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm. "This is a major step forward in prostate cancer therapeutics," said Dr Johann de Bono from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, who presented the study results at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Patients in this Phase-III ...

Fertility concerns of cancer survivors inadequately addressed, study finds

2010-10-13
Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors. Professor Bogda Koczwara from Flinders Medical Centre in Adelaide said that fertility concerns among cancer survivors was a growing problem, due to a combination of improved cancer treatment outcomes in young cancer survivors ...

Re-evaluating the time of your life

2010-10-13
In life, we're told, we must take the good with the bad, and how we view these life events determines our well-being and ability to adjust. But according to Prof. Dov Shmotkin of Tel Aviv University's Department of Psychology, you need more than the right attitude to successfully negotiate the vicissitudes of life. As recently reported in Aging and Mental Health, Prof. Shmotkin's research reveals that people's well-being and their adaptation can be ascertained by their "time trajectory" ― their concept of how they have evolved through their remembered past, currently ...

Sexual issues a major concern for cancer patients taking new targeted drugs

2010-10-13
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients. Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking ...

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

2010-10-13
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy ...

New Phase II study shows first-line promise of lung cancer drug PF-299

2010-10-13
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong. While some ...

Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer

2010-10-13
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...

Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

2010-10-13
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells. At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...

Selective strategy could lead to new approaches against schizophrenia

2010-10-13
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia. Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others. The ...

LAST 30 PRESS RELEASES:

Researchers awarded $2.5 million grant to increase lung cancer screenings in underserved communities

New trigger proposed for record-smashing 2022 Tonga eruption

Lupus Research Alliance announces Lupus Research Highlights at ACR Convergence 2024

Satellite imagery may help protect coastal forests from climate change

The secrets of baseball's magic mud

Toddlers understand concept of possibility

Small reductions to meat production in wealthier countries may help fight climate change, new analysis concludes

Scientists determine why some patients don’t respond well to wet macular degeneration treatment, show how new experimental drug can bridge gap

Did the world's best-preserved dinosaurs really die in 'Pompeii-type' events?

Not the usual suspects: Novel genetic basis of pest resistance to biotech crops

Jill Tarter to receive Inaugural Tarter Award for Innovation in the search for life beyond earth

Survey finds continued declines in HIV clinician workforce

Researchers home in on tumor vulnerabilities to improve odds of treating glioblastoma

Awareness of lung cancer screening remains low

Hospital COVID-19 burden and adverse event rates

NSF NOIRLab astronomers discover the fastest-feeding black hole in the early universe

Translational science reviews—a new JAMA review

How the keto diet could one day treat autoimmune disorders

Influence of tool corner radius on chip geometrical characteristics of machining Zr-based bulk metallic glass

Megan Huisingh-Scheetz, MD, MPH, of the University of Chicago recognized with AFAR’s Terrie Fox Wetle Rising Star Award in Health Services and Aging Research

Steven N. Austad, PhD, to receive inaugural George M. Martin Lifetime Achievement in Mentoring Award

Jeremy D. Walston, MD, of Johns Hopkins University to receive AFAR 2024 Irving S. Wright Award of Distinction

SwRI receives $23 million in U.S. Air Force contracts to sustain aging aircraft

Insilico Medicine enters into revolving loan facility of up to US$100 Million with HSBC

Security in quantum computing

Noninvasive choroidal vessel analysis via deep learning: A new approach to choroidal optical coherence tomography angiography

National Multiple Sclerosis Society awards $1M to Case Western Reserve University researchers to study new approach to treat the disease

Virginia Tech researchers find menthol restrictions may drive smokers to healthier alternatives

Japanese study reveals the importance of new overtime restrictions on physician’s mental health

Space: A new frontier for exploring stem cell therapy

[Press-News.org] Global research effort leads to new findings on genes and obesity
Einstein researcher part of team that finds genes linked to body shape and body mass index